Negocie Vir Biotechnology VIR

Venda
 Comprar

Gráfico VirBiotechnology ao vivo

5m 15m 30m 1h 4h 1d 1w

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

VirBiotechnology news

Últimas notícias

Mostrar mais
Frances Wang 2025 Jun 29, 16:00

TSLA Stock Analysis: Will Tesla Stock Go up with Robotaxi?

Stocks
Frances Wang 2025 Jun 29, 16:00

Commodity market today: Oil Prices Decline on Increased OPEC+ Supply Outlook

Commodities
Tommy Yap 2025 Jun 28, 21:00

 Week Ahead: U.S. Non-Farm Payrolls Data in the Spotlight

Forex Indices
Frances Wang 2025 Jun 26, 16:00

Stock market today: Sensex jumps, Nifty above 25,600, Dow and S&P 500 rise

Stocks
Frances Wang 2025 Jun 26, 16:00

XRP News Today: Ripple Price Slides 5%

Cryptocurrencies
Frances Wang 2025 Jun 25, 16:00

Stock Mover Today: Why BAC Stock Is Trending Now?

Stocks
Frances Wang 2025 Jun 25, 16:00

MSTR Stock News: MSTR Shares Rise 1.9% Amid Mixed Options Market Sentiment

Stocks
Ghko B 2025 Jun 25, 16:00

Stock indexes today: Dow Jumps 500 Points, S&P 500 Rises on Trump Ceasefire

Stocks

Info

Spread

0.06

Spread (%)

1.1407 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercados fechados

Segunda-feira

13:31 - 19:59

Terça-feira

13:31-19:59

Quarta-feira

13:31-19:59

Quinta-feira

13:31-19:59

Sexta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

714690496

Ações em circulação

138238000

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

Data Ex-Dividendos

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-4.23

Saiba mais sobre este instrumento

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):

Negociar agora

Negociar agora

Negociar agora

Negociar agora
Instrumentos relacionados

latest_education_articles

Mostrar mais
Trustpilot